A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

October 31, 2006

Conditions
Facial Wrinkles
Interventions
DEVICE

Hylaform, Hylaform Plus (hylan B gel)

Trial Locations (3)

19107

Society Hill Dermatology, Philadelphia

48088

Grekin Skin Institute, Warren

90036

Vitiligo & Pigmentation Institute of Southern California, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inamed Aesthetics

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00293163 - A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. | Biotech Hunter | Biotech Hunter